These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37360013)

  • 1. HR121 targeting HR2 domain in S2 subunit of spike protein can serve as a broad-spectrum SARS-CoV-2 inhibitor
    Lu Y; Shen F; He W; Li A; Li M; Feng X; Zheng Y; Pang W
    Acta Pharm Sin B; 2023 May; 13(8):3339-51. PubMed ID: 37360013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A variant-proof SARS-CoV-2 vaccine targeting HR1 domain in S2 subunit of spike protein.
    Pang W; Lu Y; Zhao YB; Shen F; Fan CF; Wang Q; He WQ; He XY; Li ZK; Chen TT; Yang CX; Li YZ; Xiao SX; Zhao ZJ; Huang XS; Luo RH; Yang LM; Zhang M; Dong XQ; Li MH; Feng XL; Zhou QC; Qu W; Jiang S; Ouyang S; Zheng YT
    Cell Res; 2022 Dec; 32(12):1068-1085. PubMed ID: 36357786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Five-Helix-Based SARS-CoV-2 Fusion Inhibitor Targeting Heptad Repeat 2 Domain against SARS-CoV-2 and Its Variants of Concern.
    Xing L; Xu X; Xu W; Liu Z; Shen X; Zhou J; Xu L; Pu J; Yang C; Huang Y; Lu L; Jiang S; Liu S
    Viruses; 2022 Mar; 14(3):. PubMed ID: 35337003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of recombinant protein-based SARS-CoV entry inhibitors targeting the heptad-repeat regions of the spike protein S2 domain.
    Ni L; Zhu J; Zhang J; Yan M; Gao GF; Tien P
    Biochem Biophys Res Commun; 2005 Apr; 330(1):39-45. PubMed ID: 15781229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
    Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
    Elife; 2022 Aug; 11():. PubMed ID: 36004719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An engineered 5-helix bundle derived from SARS-CoV-2 S2 pre-binds sarbecoviral spike at both serological- and endosomal-pH to inhibit virus entry.
    Lin X; Guo L; Lin S; Chen Z; Yang F; Yang J; Wang L; Wen A; Duan Y; Zhang X; Dai Y; Yin K; Yuan X; Yu C; He B; Cao Y; Dong H; Li J; Zhao Q; Lu G
    Emerg Microbes Infect; 2022 Dec; 11(1):1920-1935. PubMed ID: 35757908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibodies against S2 subunit of spike protein exhibit broad reactivity toward SARS-CoV-2 variants.
    Ko SH; Chen WY; Su SC; Lin HT; Ke FY; Liang KH; Hsu FF; Kumari M; Fu CY; Wu HC
    J Biomed Sci; 2022 Dec; 29(1):108. PubMed ID: 36550570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranasal booster using an Omicron vaccine confers broad mucosal and systemic immunity against SARS-CoV-2 variants.
    Wang Q; Yang C; Yin L; Sun J; Wang W; Li H; Zhang Z; Chen S; Liu B; Liu Z; Shi L; Liu X; Guan S; Wang C; Qu L; Feng Y; Niu X; Feng L; Zhao J; Li P; Chen L; Zhong N
    Signal Transduct Target Ther; 2023 Apr; 8(1):167. PubMed ID: 37069171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel cyclic γ-AApeptide-based long-acting pan-coronavirus fusion inhibitor with potential oral bioavailability by targeting two sites in spike protein.
    Xue S; Wang X; Wang L; Xu W; Xia S; Sun L; Wang S; Shen N; Yang Z; Huang B; Li S; Cao C; Calcul L; Sun X; Lu L; Cai J; Jiang S
    Cell Discov; 2022 Sep; 8(1):88. PubMed ID: 36075899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent inhibition of diverse Omicron sublineages by SARS-CoV-2 fusion-inhibitory lipopeptides.
    Zhu Y; Hu Y; Liu N; Chong H; He Y
    Antiviral Res; 2022 Dec; 208():105445. PubMed ID: 36265805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and intranasal administration of a SARS-CoV-2 broadly acting neutralizing antibody with activity against multiple Omicron subvariants.
    Duty JA; Kraus T; Zhou H; Zhang Y; Shaabani N; Yildiz S; Du N; Singh A; Miorin L; Li D; Stegman K; Ophir S; Cao X; Atanasoff K; Lim R; Mena I; Bouvier NM; Kowdle S; Carreño JM; Rivero-Nava L; Raskin A; Moreno E; Johnson S; Rathnasinghe R; Pai CI; Kehrer T; Cabral EP; Jangra S; Healy L; Singh G; Warang P; Simon V; Sordillo EM; van Bakel H; Liu Y; Sun W; Kerwin L; Teijaro J; Schotsaert M; Krammer F; Bresson D; García-Sastre A; Fu Y; Lee B; Powers C; Moran T; Ji H; Tortorella D; Allen R
    Med; 2022 Oct; 3(10):705-721.e11. PubMed ID: 36044897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern.
    Yuan M; Chen X; Zhu Y; Dong X; Liu Y; Qian Z; Ye L; Liu P
    J Virol; 2022 Aug; 96(16):e0077522. PubMed ID: 35916510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralizing Monoclonal Antibodies Inhibit SARS-CoV-2 Infection through Blocking Membrane Fusion.
    Li CJ; Chao TL; Chang TY; Hsiao CC; Lu DC; Chiang YW; Lai GC; Tsai YM; Fang JT; Ieong S; Wang JT; Chang SY; Chang SC
    Microbiol Spectr; 2022 Apr; 10(2):e0181421. PubMed ID: 35293796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fusion-inhibition peptide broadly inhibits influenza virus and SARS-CoV-2, including Delta and Omicron variants.
    Zhao H; Meng X; Peng Z; Lam H; Zhang C; Zhou X; Chan JF; Kao RYT; To KK; Yuen KY
    Emerg Microbes Infect; 2022 Dec; 11(1):926-937. PubMed ID: 35259078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.
    Xia S; Liu M; Wang C; Xu W; Lan Q; Feng S; Qi F; Bao L; Du L; Liu S; Qin C; Sun F; Shi Z; Zhu Y; Jiang S; Lu L
    Cell Res; 2020 Apr; 30(4):343-355. PubMed ID: 32231345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and Analysis of Monoclonal Antibodies with Neutralizing Activity against Diverse SARS-CoV-2 Variants.
    Ishimaru H; Nishimura M; Tjan LH; Sutandhio S; Marini MI; Effendi GB; Shigematsu H; Kato K; Hasegawa N; Aoki K; Kurahashi Y; Furukawa K; Shinohara M; Nakamura T; Arii J; Nagano T; Nakamura S; Sano S; Iwata S; Okamura S; Mori Y
    J Virol; 2023 Jun; 97(6):e0028623. PubMed ID: 37191569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasal delivery of a chimpanzee adenovirus vector expressing a pre-fusion spike (BV-AdCoV-1) protects golden Syrian hamsters against SARS-CoV-2 infection.
    Wang S; Xu L; Mu T; Qin M; Zhao P; Xie L; Du L; Wu Y; Legrand N; Mouchain K; Fichet G; Liu Y; Yin W; Zhao J; Ji M; Gong B; Klein M; Wu K
    Front Cell Infect Microbiol; 2022; 12():979641. PubMed ID: 36405962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the SARS-CoV-2 BA.5.5 and BQ.1.1 Omicron Variants in Mice and Hamsters.
    Case JB; Scheaffer SM; Darling TL; Bricker TL; Adams LJ; Harastani H; Trende R; Sanapala S; Fremont DH; Boon ACM; Diamond MS
    bioRxiv; 2023 May; ():. PubMed ID: 37205409
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.